Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608354 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT07608354 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 326 participants.
The verdict
NCT07608354, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Interventions
- OTHER Placebo
- DRUG Eplontersen
- BIOLOGICAL ALXN2220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2029-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07608354
The ClinicalTrials.gov registry entry for NCT07608354 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07608354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07608354 about?
NCT07608354 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM". The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
What is the current status of trial NCT07608354?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2026-06-11. Estimated completion is 2029-02-06.
What interventions are being tested in trial NCT07608354?
The interventions under investigation include: Placebo (OTHER), Eplontersen (DRUG), ALXN2220 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07608354?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.